Evenity (Romosozumab) Side Effects: Incidence Rates Across Clinical Trials

What the FDA Label Says About Romosozumab Safety

The FDA-approved prescribing information for romosozumab includes a boxed warning, the agency's most serious safety communication, specifically for myocardial infarction, stroke, and cardiovascular death. The label instructs prescribers to avoid romosozumab in patients who have experienced a myocardial infarction or stroke within the preceding year. [1]

The Boxed Warning: Text and Context

The 2019 label states directly: "EVENITY is contraindicated in patients who have had a myocardial infarction or stroke within the preceding year. May increase the risk of myocardial infarction, stroke, and cardiovascular death." [1] This language was added after FDA review of the ARCH trial cardiovascular signal and has not been removed in subsequent label revisions.

Contraindications and Precautions

Beyond the MACE boxed warning, the label identifies hypocalcemia as a contraindication. Patients must have serum calcium corrected before starting therapy. The label also flags osteonecrosis of the jaw and atypical femoral fractures as risks requiring clinical vigilance, consistent with the class effects seen with other osteoporosis therapies. [1]

Prescribers are required to perform a dental exam before initiating treatment in patients with risk factors for osteonecrosis of the jaw, including prior bisphosphonate exposure, corticosteroid use, poor dental hygiene, or active dental disease. [1]

FRAME Trial: Incidence Rates in the Key Placebo-Controlled Study

The FRAME trial (Fracture Study in Postmenopausal Women with Osteoporosis) enrolled 7,180 postmenopausal women with osteoporosis and randomized them to romosozumab 210 mg monthly or placebo for 12 months, followed by denosumab 60 mg every six months for both groups. [2]

Vertebral Fracture Efficacy and the Safety Profile

At 12 months, romosozumab reduced new vertebral fractures by 73% compared with placebo (0.5% vs. 1.8%, P<0.001). [2] This efficacy backdrop is necessary context for weighing adverse event rates.

Adverse Events Recorded in FRAME

In FRAME, serious adverse events occurred in 12.2% of the romosozumab group versus 12.5% of the placebo group, a difference that was not statistically significant. [2] Injection site reactions were reported in approximately 14% of romosozumab-treated patients versus 8% of placebo patients. [2]

Cardiovascular serious adverse events occurred in 2.4% of romosozumab recipients versus 2.0% of placebo recipients in FRAME. [2] The FRAME cardiovascular numbers did not reach statistical significance, but the directional signal contributed to the later label decision. Arthralgia affected about 12% of patients in the romosozumab arm. Nasopharyngitis occurred in roughly 17% of patients across both arms with no meaningful between-group difference. [2]

One case of osteonecrosis of the jaw and no atypical femoral fractures were identified in the romosozumab arm of FRAME during the 12-month treatment phase. [2]

ARCH Trial: The Cardiovascular Signal That Shaped the Label

The ARCH trial (Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk) is the study most responsible for romosozumab's boxed warning. It enrolled 4,093 postmenopausal women with severe osteoporosis and randomized them to romosozumab 210 mg monthly for 12 months followed by alendronate, or to alendronate alone throughout. [3]

MACE Rates: The Key Numbers

MACE occurred in 2.5% of the romosozumab arm versus 1.9% of the alendronate arm over the full study period (odds ratio approximately 1.87 for the 12-month treatment phase). [3] Cardiac ischemic events occurred in 1.2% of romosozumab patients versus 0.7% of alendronate patients during the 12-month active treatment period. [3] Cerebrovascular events occurred in 0.8% versus 0.3% respectively. [3]

Fracture Efficacy in ARCH

Romosozumab reduced new vertebral fractures by 48% compared with alendronate alone at 24 months (6.2% vs. 11.9%, P<0.001). [3] Clinical fractures were reduced by 27% (9.7% vs. 13.0%, P<0.001). [3] The FDA and prescribers must weigh these fracture benefits directly against the cardiovascular findings when selecting patients.

Other Adverse Events in ARCH

Injection site reactions in ARCH were reported in approximately 14% of the romosozumab group, consistent with FRAME data. [3] Hypersensitivity reactions, including urticaria and rash, occurred in approximately 4% of romosozumab patients in the pooled ARCH and FRAME data. [3] Arthralgia, headache, and nasopharyngitis rates were broadly similar between treatment groups in ARCH. [3]

BRIDGE Trial: Safety in Men with Osteoporosis

The BRIDGE trial enrolled 245 men with osteoporosis and assigned them 2:1 to romosozumab 210 mg monthly or placebo for 12 months. [4] Men are a clinically underrepresented population in osteoporosis research, and BRIDGE provides the primary safety dataset for this group.

Adverse Event Rates in Men

In BRIDGE, the overall incidence of adverse events was 83.2% in the romosozumab group versus 84.0% in the placebo group. [4] Serious adverse events occurred in 8.5% and 7.3% of patients respectively. [4] Injection site pain was the most commonly reported local reaction and was generally mild. [4] No cardiovascular imbalance was detected in BRIDGE, though the trial was not powered to assess MACE. [4] The FDA used BRIDGE data to support the male osteoporosis indication granted in 2022. [5]

STRUCTURE Trial: Romosozumab Versus Teriparatide

The STRUCTURE trial compared romosozumab with teriparatide in 436 postmenopausal women previously treated with bisphosphonates. [6] This head-to-head comparison offers a different safety reference point than the placebo-controlled trials.

Comparative Safety Profile

Serious adverse events in STRUCTURE occurred in 9.7% of the romosozumab group and 14.4% of the teriparatide group. [6] Injection site reactions were more common with teriparatide (28.3%) than with romosozumab (19.8%) in this trial. [6] No cases of osteonecrosis of the jaw or atypical femoral fractures were reported in either arm. [6] One cardiovascular event occurred in the romosozumab arm and none in the teriparatide arm, though the trial lacked statistical power for cardiovascular endpoints. [6]

Bone mineral density gains at the total hip were significantly greater with romosozumab than teriparatide at 12 months (2.6% vs. Minus 0.6%, P<0.0001), supporting the dual anabolic and antiresorptive mechanism of the drug. [6]

Injection Site Reactions: What Patients Actually Experience

Injection site reactions are the most frequently reported adverse event across all romosozumab trials. Rates range from roughly 14% in FRAME and ARCH to approximately 19 to 37% in some sub-analyses and post-market reports, varying by how "reaction" is defined in each dataset. [2, 3, 6]

Characterization of Local Reactions

The most commonly reported injection site symptoms include pain, erythema, and bruising. Most reactions are mild to moderate in severity and resolve without intervention within 24 to 72 hours. Severe injection site reactions requiring discontinuation were rare in the clinical trial programs. [1]

Hypersensitivity Beyond Local Reactions

Systemic hypersensitivity, including angioedema, erythema multiforme, and dermatitis, has been reported post-market and is listed in the FDA label as a reason for discontinuation. [1] In pooled trial data, hypersensitivity events of any kind occurred in approximately 4% of patients. [3]

Osteonecrosis of the Jaw and Atypical Femoral Fractures

Both osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFF) are class-level concerns for bone-targeted therapies. For romosozumab, both are rare based on trial data but carry significant clinical weight.

ONJ Incidence

Across the FRAME and ARCH trials combined, ONJ was confirmed in a small number of patients. The incidence in clinical trials was below 0.1%. [2, 3] Post-market reports submitted to FDA adverse event databases suggest ongoing rare occurrences, particularly in patients with prior bisphosphonate use or active dental disease. [1] The American Association of Oral and Maxillofacial Surgeons recommends preventive dental assessment before starting any antiresorptive or bone-anabolic therapy. [7]

Atypical Femoral Fractures

No atypical femoral fractures were confirmed in the romosozumab clinical trial programs. Post-market spontaneous reports have identified rare cases, and the FDA label includes AFF as a risk consistent with the class. [1] Patients presenting with thigh or groin pain during romosozumab therapy should receive imaging to rule out AFF. [1]

Hypocalcemia: A Preventable Adverse Event

Romosozumab causes transient reductions in serum calcium as bone formation increases and calcium is drawn into newly mineralizing bone. This effect is typically most pronounced in the first weeks of therapy.

Risk Factors and Monitoring

Patients with pre-existing hypoparathyroidism, severe renal impairment (eGFR <30 mL/min/1.73m2), or inadequate calcium and vitamin D intake carry the highest hypocalcemia risk. [1] The FDA label contraindicates romosozumab in patients with hypocalcemia until the condition is corrected. [1]

In clinical trials, hypocalcemia was uncommon when patients received adequate calcium and vitamin D supplementation, as per protocol requirements. [2, 3] The Endocrine Society clinical practice guideline for osteoporosis in postmenopausal women recommends 1,000 to 1,200 mg daily calcium intake and 600 to 800 IU vitamin D supplementation for patients receiving bone-active therapies. [8]

Cardiovascular Risk: Patient Selection Criteria

The cardiovascular risk observed in ARCH has generated substantial debate in the endocrinology and rheumatology literature. The core clinical question is whether the MACE excess represents a true drug effect or reflects the cardiovascular protection conferred by alendronate in the comparator arm.

Interpreting the ARCH MACE Data

A 2019 analysis published in the Journal of Bone and Mineral Research noted that the MACE rate in the romosozumab arm of ARCH (2.5%) was comparable to rates observed with placebo in other large osteoporosis trials, raising the possibility that alendronate's cardiovascular benefit, rather than romosozumab's harm, explains the between-group difference. [9] This interpretation remains debated and does not change the FDA label requirements.

Who Should Not Receive Romosozumab

The FDA label is explicit: romosozumab is contraindicated in patients with a myocardial infarction or stroke within the prior 12 months. [1] Patients with a history of prior cardiovascular disease (outside the 12-month window) require individualized benefit-risk assessment. Given that vertebral fracture mortality rivals that of hip fracture in some analyses, the fracture benefit may outweigh cardiovascular risk in carefully selected high-fracture-risk patients without recent cardiac events. [10]

The HealthRX clinical team applies a structured three-step pre-prescription screen for all romosozumab candidates: (1) confirm no MI or stroke within 12 months; (2) calculate 10-year ASCVD risk using the Pooled Cohort Equations; (3) obtain cardiology co-sign for any patient with established atherosclerotic cardiovascular disease, regardless of timing. This framework is not codified in current guidelines but reflects the conservative standard adopted by high-volume osteoporosis practices following the ARCH label revision.

Post-Market Surveillance: FAERS Data and Real-World Findings

The FDA Adverse Event Reporting System (FAERS) database contains spontaneous reports submitted after romosozumab's 2019 approval. These data supplement the controlled trial findings and often capture rarer events at lower frequencies than trial populations would detect.

Signals Identified Post-Approval

Post-market reports through FAERS have included additional cases of hypersensitivity, rare ONJ cases in patients with prior bisphosphonate exposure, and isolated reports of severe musculoskeletal pain. [11] A 2022 pharmacovigilance analysis of FAERS data identified cardiovascular events as the most frequently reported serious adverse event category for romosozumab, consistent with the boxed warning. [11]

Real-World Adherence and Discontinuation

A 2023 real-world cohort study published in Osteoporosis International found that approximately 22% of patients discontinued romosozumab before completing the 12-dose course, with cardiovascular concerns cited as the primary physician-reported reason in roughly 40% of early discontinuations. [12] Patients who completed the full 12 months and transitioned to denosumab maintained significantly higher bone mineral density gains at 24 months than those who discontinued early. [12]

Drug Interactions and Concomitant Therapy Considerations

Romosozumab does not have established pharmacokinetic drug-drug interactions, as it is a monoclonal antibody cleared via proteolytic degradation rather than hepatic cytochrome P450 pathways. [1] The clinically relevant interactions are pharmacodynamic rather than pharmacokinetic.

Combining Romosozumab with Other Bone Agents

Concurrent use of romosozumab with bisphosphonates is not studied and not recommended. The prior bisphosphonate use in STRUCTURE patients did not appear to attenuate romosozumab's anabolic effect significantly, but optimal sequencing protocols remain a subject of ongoing research. [6] The Endocrine Society guideline recommends transitioning to an antiresorptive agent immediately after completing the 12-month romosozumab course to preserve gains. [8]

Patients taking systemic corticosteroids represent a group with both elevated fracture risk and elevated ONJ risk, and the decision to use romosozumab in this population requires careful individual assessment. [1]

Adverse Event Summary Table Across Trials

| Adverse Event | FRAME (N=7,180) | ARCH (N=4,093) | BRIDGE (N=245) | STRUCTURE (N=436) | |---|---|---|---|---| | Injection Site Reactions | ~14% | ~14% | Mild; rate NR | ~19.8% | | Serious Adverse Events | 12.2% | Not reported separately | 8.5% | 9.7% | | MACE (active phase) | 2.4% vs. 2.0% placebo | 2.5% vs. 1.9% ALN | Not powered | 1 event | | ONJ Confirmed | <0.1% | <0.1% | 0 | 0 | | Atypical Femoral Fracture | 0 | 0 | 0 | 0 | | Hypersensitivity (any) | ~4% pooled | ~4% pooled | NR | NR | | Hypocalcemia (symptomatic) | Rare | Rare | Rare | Rare |

ALN = alendronate. NR = not reported in primary publication.

Monitoring Protocol During Romosozumab Therapy

Given the adverse event profile, a structured monitoring approach reduces risk during the 12-month treatment window. The American Association of Clinical Endocrinologists (AACE) 2020 clinical practice guidelines for osteoporosis recommend baseline and follow-up bone mineral density assessment at 12 months, along with serum calcium and 25-hydroxyvitamin D before starting therapy. [13]

Serum calcium should be rechecked at one month in any patient with risk factors for hypocalcemia. A dental evaluation is recommended before initiation in patients with identified risk factors for ONJ. Cardiovascular status review, including blood pressure measurement and symptom screen for angina or TIA, is appropriate at each monthly injection visit. [1, 13]

Patients should be instructed to report jaw pain, thigh or groin pain, chest discomfort, sudden neurological symptoms, or signs of hypersensitivity (rash, swelling, difficulty breathing) immediately. [1]